CIK 0001997038
Iambic Therapeutics, Inc.
Sign in to watch- Ticker
- IAM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- other
- EIN
- 843364168
- Phone
- (626) 592-2520
- Business address
- 5627 OBERLIN DRIVE, SUITE 120, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $11,500,000
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$11,500,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-16 | Rachlin Evan Lockwood Director | Conversion | +1,458,736 | 1,458,736 | ||
| 2026-10-16 | Rachlin Evan Lockwood Director | Conversion | +410,762 | 1,869,498 | ||
| 2026-10-16 | Rachlin Evan Lockwood Director | Purchase | +718,750 | $16.00 | $11.5M | 2,588,248 |
| 2026-10-16 | Rachlin Evan Lockwood Director | Conversion | +57,754 | 57,754 | ||
| 2026-10-16 | Rachlin Evan Lockwood Director | Conversion · Series B Convertible Preferred Stock | −1,152,025 | 0 | ||
| 2026-10-16 | Rachlin Evan Lockwood Director | Conversion · Series B Convertible Preferred Stock | −57,754 | 0 | ||
| 2026-10-16 | Rachlin Evan Lockwood Director | Conversion · Series B-3 Convertible Preferred Stock | −306,711 | 0 | ||
| 2026-10-16 | Rachlin Evan Lockwood Director | Conversion · Convertible Promissory Notes | −410,762 | 0 | ||
| 2026-10-14 | Rachlin Evan Lockwood Director | Grant or award · Stock Option (right to buy) | +20,300 | 20,300 |
Page 1 of 1 · 9 trades